Longeveron (LGVN) Cost of Revenue (2020 - 2026)
Longeveron (LGVN) posted quarterly Cost of Revenue of $134000.0 for Q1 2026, up 26.42% year-over-year from $106000.0 in Q1 2025, and up 24.07% quarter-over-quarter from $108000.0 in Q4 2025.
Longeveron (LGVN) Cost of Revenue (2020 - 2026) Analysis & Trends
Longeveron's Cost of Revenue history runs 7 years deep, the most recent figure standing at $134000.0 for Q1 2026.
- In Q1 2026, Cost of Revenue rose 26.42% year-over-year to $134000.0; the TTM figure through Mar 2026 stood at $424000.0 (up 7.61% YoY), while the FY2025 annual figure was $396000.0, down 22.05% from the prior year.
- Cost of Revenue for Q1 2026 stood at $134000.0, up from $108000.0 in the prior quarter.
- The five-year high for Cost of Revenue was $306000.0 in Q2 2022, with the low at $12000.0 in Q3 2025.
- The 5-year median for Cost of Revenue is $124000.0 (2023), against an average of $140294.1.
- The sharpest annual moves came in 2022 and 2025: Cost of Revenue soared 154.41% in 2022, then slumped 86.81% in 2025.
- Longeveron's Cost of Revenue stood at $176000.0 in 2022, then plunged by 63.07% to $65000.0 in 2023, then increased by 12.31% to $73000.0 in 2024, then surged by 47.95% to $108000.0 in 2025, then grew by 24.07% to $134000.0 in 2026.
- Business Quant data shows LGVN's Cost of Revenue at $134000.0 in Q1 2026, $108000.0 in Q4 2025, and $12000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 489.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 360.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 145.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 93.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 174.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 298.26 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 387.98 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 67.21 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Longeveron | 26.51 Mn | 16.41 Mn | 182,000.00 | 105,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 105,000.00 |
| Jun 30, 2026 | 105,000.00 |
| Mar 31, 2026 | 134,000.00 |
| Mar 31, 2026 | 134,000.00 |
| Dec 31, 2025 | 108,000.00 |
| Dec 31, 2025 | 108,000.00 |
| Sep 30, 2025 | 12,000.00 |
| Sep 30, 2025 | 12,000.00 |
| Jun 30, 2025 | 170,000.00 |
| Jun 30, 2025 | 170,000.00 |
| Mar 31, 2025 | 106,000.00 |
| Mar 31, 2025 | 106,000.00 |
| Dec 31, 2024 | 73,000.00 |
| Dec 31, 2024 | 73,000.00 |
| Sep 30, 2024 | 91,000.00 |
| Sep 30, 2024 | 91,000.00 |
| Jun 30, 2024 | 124,000.00 |
| Jun 30, 2024 | 124,000.00 |
| Mar 31, 2024 | 219,000.00 |
| Mar 31, 2024 | 219,000.00 |